NICE
Discount fails to sway NICE on Gilenya
December 1, 2011Sales and Marketing NICE, Novartis, gilenya
NICE has once again rejected Novartis’ multiple sclerosis pill Gilenya despite the firm offering a patient access scheme. In its …
NICE wishes you a cost effective Christmas
November 30, 2011Sales and Marketing NICE
NICE has disclosed information about its use of corporate credit cards following a request made under the Freedom of Information …
NICE rejects Lucentis in diabetic macular oedema
November 29, 2011Sales and Marketing Lucentis, NICE
NICE has rejected Novartis’ Lucentis for diabetic macular oedema. NICE has not recommended Lucentis (ranibizumab) for the treatment of diabetic …
NICE okays Eliquis for blood clots after surgery
November 25, 2011Research and Development, Sales and Marketing BMS, Eliquis, NICE, Pfizer
NICE is recommending Pfizer and Bristol-Myers Squibb’s Eliquis for blood clots after surgery. Specifically, NICE has said that Eliquis (apixaban) …
Lucentis not backed by NICE for new licence
November 24, 2011Sales and Marketing Lucentis, NICE, Novartis, Ozurdex
NICE has not recommended Novartis’ eye disease drug Lucentis due to ‘gaps and uncertainties’ in the manufacturer’s submission. In draft …
Professor Sir Michael Rawlins reappointed as NICE chairman
November 24, 2011Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, Rawlins
The National Institute for Health and Clinical Excellence (NICE) has reappointed Professor Sir Michael Rawlins as NICE chairman for a …
NICE will not back Eisai’s Halaven
November 17, 2011Medical Communications, Sales and Marketing Eisai, Halaven, NICE, breast cancer
NICE has not recommended Eisai’s novel breast cancer drug Halaven due to concerns over its safety and cost.In draft guidance …
NICE won’t back Faslodex in breast cancer
November 10, 2011Sales and Marketing AstraZeneca, Faslodex, NICE
NICE has not recommended AstraZeneca’s breast cancer drug Faslodex as it says the drug is no better than existing treatments. …
NICE U-turn on Boehringer’s Pradaxa
November 1, 2011Sales and Marketing NICE, Pradaxa
NICE is now recommending Boehringer Ingelheim’s Pradaxa for stroke prevention after initially rejecting the drug on cost-effectiveness issues. NICE has …
Brilique gains NICE approval
October 31, 2011Sales and Marketing ACS, Brilique, NICE, Plavix, clopidogrel
AstraZeneca’s Brilique has been approved by NICE for use in combination with aspirin as an option to treat patients with …
Mepact wins NICE backing
October 26, 2011Research and Development, Sales and Marketing Mepact, NICE
NICE has recommended Takeda’s bone cancer drug Mepact after the firm offered a discount for the treatment. The watchdog’s final …
NICE recommends Lilly’s long-acting Bydureon
October 18, 2011Sales and Marketing Bydureon, NICE, diabetes
NICE has recommended Eli Lilly’s long-acting diabetes drug Bydureon after the failure of oral treatments. Bydureon (exenatide) – a long-acting …
NICE: Bristol-Myers Squibb’s Yervoy too costly
October 14, 2011Sales and Marketing NICE, Yervoy
Bristol Myers Squibb has failed to win NICE backing for its melanoma drug Yervoy after the Institute judged its £80,000 …
